Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 11, 2022

Subgroup Analysis by Disease History and Prior Treatments of Patients With HER2+ MBC Treated With Trastuzumab Deruxtecan vs Trastuzumab Emtansine

Annals of Oncology


Additional Info

Annals of Oncology
236P Subgroup analysis by disease history and prior treatments of patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1)
Ann. Oncol 2022 Sep 01;33(suppl 7)S645-S646, J Cortés, SA Im, H Iwata, et al

Further Reading